Search

LeWitt, PA, SD Aradi, RA Hauser, and O Rascol. 2020. “The Challenge of Developing Adenosine A2A antagonists for Parkinson Disease: Istradefylline, Preladenant, and Tozadenant. Parkinsonism Relat Disord 2020;80 Suppl 1:S54-S63.”. Parkinsonism Relat Disord.

Cisbani, G, TB Freeman, D Soulet, Saint Pierre, D Gagnon, M Parent, RA Hauser, RA Barker, and F Cicchetti. 2013. “Striatal Allografts in Patients With Huntington’s Disease: Impact of Diminished Astrocytes and Vascularization on Graft Viability. Brain 2013;136(Pt 2):433-43..”

Hauser, RA, A Ellenbogen, S Khanna, S Gupta, and NB Modi. 2018. “Onset and Duration of Effect of Extended-Release Carbidopa-Levodopa in Advanced Parkinson’s Disease. Neuropsychiatr Dis Treat 2018;14:839-845.”. Neuropsychiatr Dis Treat.

Fernandez, HH, D Stamler, MD Davis, SA Factor, RA Hauser, J Jimenez-Shahed, WG Ondo, LF Jarskog, SW Woods, and D Bega. 2019. “Long-Term Safety and Efficacy of Deutetrabenazine for the Treatment of Tardive Dyskinesia. J Neurol Neurosurg Psychiatry 2019;90:1317-1323.”. J Neurol Neurosurg Psychiatry.

Francois, C, GJ Rowse, LA Hewitt, P Vo, and RA Hauser. 2016. “Analysis of Number Needed to Treat for Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension. BMC Neurol 2016;16:143.”. BMC Neurol.

Hauser, RA, H Reichmann, M Lew, A Asgharian, C Makumi, and KJ Shulman. 2011. “Long-Term, Open-Label Study of Once-Daily Ropinirole Prolonged Release in Early Parkinson’s Disease. Int J Neurosci 2011;121:246-53.”. Int J Neurosci.

Pahwa, R, KE Lyons, RA Hauser, S Fahn, J Jankovic, E Pourcher, A Hsu, M O’Connell, S Kell, and S Gupta. 2014. “Randomized Trial of IPX066, Carbidopa/Levodopa Extended Release, in Early Parkinson’s Disease. Parkinsonism Relat Disord 2014;20:142-8.”. Relat Disord.

Hauser, RA, P Auinger, and Parkinson Study Group. 2012. “Determination of Minimal Clinically Important Change in Early and Advanced Parkinson’s Disease. Mov Disord 2011;26:813-8.”. Mov Disord.

Poewe, W, O Rascol, P Barone, RA Hauser, Y Mizuno, M Haaksma, L Salin, N Juhel, and AH Shapira. 2011. “Extended-Release Pramipexole in Early Parkinson Disease: A 33-Week Randomized Controlled Trial”. Neurology.

Lyons, KE, JH Friedman, N Hermanowicz, SH Isaacson, RA Hauser, BP Hersh, DE Silver, et al. 2010. “Orally Disintegrating Selegiline in Parkinson Patients With Dopamine Agonist-Related Adverse Effects”. Clin Neuropharmacol.